In summary, the enhanced expression of US11, together with the deletion of UL34.5 and US12, allows T-VEC to replicate successfully in tumor cells by suppressing cellular antiviral response, while simultaneously promoting a robust immune response to infection, resulting in tumor-specific killing properties of this OV. Here, RPS14 is linked to neoplasm.